Deuruxolitinib CAS# 1513883-39-0

Deuruxolitinib (CP-543) demonstrates potent and selective bioactivity, functioning as a nanomolar-range inhibitor of Janus kinases JAK1 and JAK2 in vitro, with IC50 values of approximately 2.4 nM and 2.6 nM, respectively, while showing significantly lower affinity for JAK3 (IC50 ~ 284 nM), thereby highlighting its selectivity profile. This potent JAK1/JAK2 inhibition effectively suppresses the cytokine-induced phosphorylation of Signal Transducer and Activator of Transcription (STAT) proteins in cellular assays, a key signaling pathway in inflammatory diseases. In vivo, this activity translates to robust efficacy in animal models of alopecia areata (AA), where oral administration in the C3H/HeJ mouse model significantly reduced inflammatory cytokine production and reversed the disease phenotype, as evidenced by a marked dose-dependent promotion of hair regrowth, with high-dose treatment achieving near-complete hair regrowth scores and a substantial reduction in the autoimmune attack on hair follicles.